SK bioscience Co.,Ltd. (302440.KS)
302440.KS Stock Price Chart
Explore SK bioscience Co.,Ltd. interactive price chart. Choose custom timeframes to analyze 302440.KS price movements and trends.
302440.KS Company Profile
Discover essential business fundamentals and corporate details for SK bioscience Co.,Ltd. (302440.KS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Mar 2021
Employees
984.00
Website
https://www.skbioscience.co.krCEO
Jae-Yong Ahn
Description
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
302440.KS Financial Timeline
Browse a chronological timeline of SK bioscience Co.,Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 23 Oct 2025
EPS estimate is -₩372.19, while revenue estimate is ₩161.40B.
Earnings released on 31 Jul 2025
EPS came in at -₩210.00 surpassing the estimated -₩372.19 by +43.58%, while revenue for the quarter reached ₩161.86B , missing expectations by -4.79%.
Earnings released on 7 May 2025
EPS came in at -₩95.00 surpassing the estimated -₩321.48 by +70.45%, while revenue for the quarter reached ₩154.56B , beating expectations by +13.92%.
Earnings released on 5 Feb 2025
EPS came in at -₩82.16 surpassing the estimated -₩412.97 by +80.10%, while revenue for the quarter reached ₩156.85B , beating expectations by +32.92%.
Earnings released on 24 Oct 2024
EPS came in at -₩290.00 falling short of the estimated -₩131.68 by -120.23%, while revenue for the quarter reached ₩61.65B , beating expectations by +77.94K%.
Earnings released on 31 Jul 2024
EPS came in at -₩148.00 surpassing the estimated -₩257.43 by +42.51%, while revenue for the quarter reached ₩26.78B , missing expectations by -0.46%.
Earnings released on 2 May 2024
EPS came in at -₩179.00 surpassing the estimated -₩238.82 by +25.05%, while revenue for the quarter reached ₩22.27B , missing expectations by -41.39%.
Earnings released on 1 Feb 2024
EPS came in at ₩54.00 surpassing the estimated -₩119.26 by +145.28%, while revenue for the quarter reached ₩90.60B , beating expectations by +45.75%.
Earnings released on 26 Oct 2023
EPS came in at ₩630.00 surpassing the estimated ₩437.30 by +44.07%, while revenue for the quarter reached ₩231.83B .
Earnings released on 28 Jul 2023
EPS came in at -₩208.00 falling short of the estimated -₩19.16 by -985.59%, while revenue for the quarter reached ₩26.48B , beating expectations by +1.06%.
Earnings released on 27 Apr 2023
EPS came in at -₩186.00 falling short of the estimated ₩124.85 by -248.98%, while revenue for the quarter reached ₩20.60B , missing expectations by 0.00%.
Earnings released on 8 Feb 2023
EPS came in at ₩360.00 falling short of the estimated ₩492.90 by -26.96%, while revenue for the quarter reached ₩140.30B , missing expectations by 0.00%.
Earnings released on 31 Oct 2022
EPS came in at ₩270.00 surpassing the estimated ₩268.26 by +0.65%, while revenue for the quarter reached ₩91.05B , missing expectations by -14.68%.
Earnings released on 28 Jul 2022
EPS came in at ₩599.00 falling short of the estimated ₩828.74 by -27.72%, while revenue for the quarter reached ₩138.28B , missing expectations by -0.68%.
Earnings released on 29 Apr 2022
EPS came in at ₩361.04 falling short of the estimated ₩1.33K by -72.83%, while revenue for the quarter reached ₩87.09B , missing expectations by -31.21%.
Earnings released on 7 Feb 2022
EPS came in at ₩2.39K falling short of the estimated ₩2.58K by -7.45%, while revenue for the quarter reached ₩450.86B , missing expectations by -0.01%.
Earnings released on 29 Oct 2021
EPS came in at ₩1.01K , while revenue for the quarter reached ₩220.83B .
Earnings released on 30 Jul 2021
EPS came in at ₩688.00 , while revenue for the quarter reached ₩144.60B .
Earnings released on 14 May 2021
EPS came in at ₩654.00 , while revenue for the quarter reached ₩112.71B .
Earnings released on 23 Mar 2021
EPS came in at ₩526.00 , while revenue for the quarter reached ₩98.69B .
Earnings released on 31 Dec 2020
EPS came in at ₩1.61K , while revenue for the quarter reached ₩67.01B .
302440.KS Stock Performance
Access detailed 302440.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.